Tumor Necrosis Factor Blocker [EPC]

749209 reported adverse events

Drugs of this class: ETANERCEPT INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	83782
1	INJECTION SITE PAIN	56742
2	ARTHRALGIA	45923
3	RHEUMATOID ARTHRITIS	41344
4	INJECTION SITE ERYTHEMA	41226
5	PAIN	40810
6	OFF LABEL USE	32905
7	FATIGUE	29881
8	PSORIASIS	26733
9	HEADACHE	25998

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	INJECTION SITE RECALL REACTION	481	0.9796
1	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	282	0.9758
2	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	1266	0.8934
3	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1405	0.8418
4	RHEUMATOID FACTOR POSITIVE	1629	0.8414
5	C-REACTIVE PROTEIN ABNORMAL	2176	0.7819
6	INJECTION SITE MACULE	468	0.7312
7	PEMPHIGUS	2855	0.7023
8	SYNOVITIS	5972	0.6723
9	HAND DEFORMITY	3234	0.6391

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]